Teva Pharmaceutical announced on Tuesday that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD).
“Chorea associated with Huntington’s disease has a significant impact on those living with the disease and their families,” said Louise Vetter, Chief Executive Officer of the Huntington’s Disease Society of America. “The FDA’s approval of AUSTEDO represents an important new treatment option for people with HD and highlights the need for more therapeutic resources for this underserved patient community.”
A rare and fatal neurodegenerative disorder, HD affects more than 35,000 people in the United States. Chorea – involuntary, random and sudden, twisting and/or writhing movements – is one of the most striking physical manifestations of this disease and occurs in approximately 90 percent of patients